Boston Scientific (NYSE:BSX) Earns Buy Rating from BTIG Research

Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $80.00 price objective on the medical equipment provider’s stock. BTIG Research’s price target would suggest a potential upside of 46.76% from the stock’s current price.

Other research analysts also recently issued reports about the company. Oppenheimer set a $90.00 price objective on Boston Scientific in a report on Thursday, April 23rd. TD Cowen cut their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Robert W. Baird decreased their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Trading Up 3.5%

BSX traded up $1.83 on Monday, hitting $54.51. The company had a trading volume of 3,076,588 shares, compared to its average volume of 16,452,895. The business’s fifty day simple moving average is $63.40 and its 200 day simple moving average is $81.65. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific has a 12-month low of $52.52 and a 12-month high of $109.50. The company has a market cap of $81.01 billion, a PE ratio of 22.89, a PEG ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific will post 3.38 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth $26,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.